BR112023001049A2 - Método para tratamento de doença de enxerto versus hospedeiro causada por transplante de célula-tronco hematopoiética - Google Patents

Método para tratamento de doença de enxerto versus hospedeiro causada por transplante de célula-tronco hematopoiética

Info

Publication number
BR112023001049A2
BR112023001049A2 BR112023001049A BR112023001049A BR112023001049A2 BR 112023001049 A2 BR112023001049 A2 BR 112023001049A2 BR 112023001049 A BR112023001049 A BR 112023001049A BR 112023001049 A BR112023001049 A BR 112023001049A BR 112023001049 A2 BR112023001049 A2 BR 112023001049A2
Authority
BR
Brazil
Prior art keywords
stem cell
hematopoietic stem
host disease
disease caused
cell transplantation
Prior art date
Application number
BR112023001049A
Other languages
English (en)
Inventor
Cheng Cheungling
Zhao Yanping
Wang Hongjun
Zhong Weiting
Li Jing
Zhao Jing
Liu Weina
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of BR112023001049A2 publication Critical patent/BR112023001049A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

MÉTODO PARA TRATAMENTO DE DOENÇA DE ENXERTO VERSUS HOSPEDEIRO CAUSADA POR TRANSPLANTE DE CÉLULA-TRONCO HEMATOPOIÉTICA. Um método para prevenir, aliviar e/ou tratar a doença do enxerto versus hospedeiro causada pelo transplante de células-tronco hematopoiéticas, consistindo em administrar uma quantidade efetiva de um composto de fórmula (I), ou um sal farmaceuticamente aceitável, éster, esteroisômero, polimorfo, solvato, N-óxido, composto marcado com isótopos, metabólito ou profármaco do mesmo a um indivíduo necessitado.
BR112023001049A 2020-07-22 2021-07-21 Método para tratamento de doença de enxerto versus hospedeiro causada por transplante de célula-tronco hematopoiética BR112023001049A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010713637 2020-07-22
PCT/CN2021/107575 WO2022017412A1 (zh) 2020-07-22 2021-07-21 治疗造血干细胞移植后的移植物抗宿主病的方法

Publications (1)

Publication Number Publication Date
BR112023001049A2 true BR112023001049A2 (pt) 2023-03-07

Family

ID=79728482

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023001049A BR112023001049A2 (pt) 2020-07-22 2021-07-21 Método para tratamento de doença de enxerto versus hospedeiro causada por transplante de célula-tronco hematopoiética

Country Status (11)

Country Link
US (1) US20230285393A1 (pt)
EP (1) EP4186508A1 (pt)
JP (1) JP2023535035A (pt)
KR (1) KR20230043891A (pt)
CN (1) CN116322670A (pt)
AU (1) AU2021313124A1 (pt)
BR (1) BR112023001049A2 (pt)
CA (1) CA3186564A1 (pt)
IL (1) IL299985A (pt)
TW (2) TW202216691A (pt)
WO (1) WO2022017412A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023041026A1 (zh) * 2021-09-18 2023-03-23 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂或其溶剂合物的固体形式及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011009568A (es) * 2009-03-09 2011-12-06 Surface Logix Inc Inhibidores de la rho cinasa.
EA201500362A1 (ru) * 2012-10-05 2015-08-31 Кадмон Корпорейшн, Ллк Ингибиторы rho-киназы
EP3504204A4 (en) * 2016-08-26 2020-05-27 Lycera Corporation INDAZOLYL-L, 2,4-THIADIAZOLAMINE AND RELATED COMPOUNDS FOR INHIBITING RHO-ASSOCIATED PROTEIN KINASES AND FOR TREATING DISEASES
CN110582489B (zh) 2017-06-30 2023-10-27 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
KR102469161B1 (ko) * 2017-06-30 2022-11-23 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Ｒｈｏ-관련 단백질 키나아제 억제제, Ｒｈｏ-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도
EP3421465B1 (en) * 2017-06-30 2022-10-26 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof

Also Published As

Publication number Publication date
TW202216691A (zh) 2022-05-01
KR20230043891A (ko) 2023-03-31
US20230285393A1 (en) 2023-09-14
WO2022017412A1 (zh) 2022-01-27
CN116322670A (zh) 2023-06-23
EP4186508A1 (en) 2023-05-31
JP2023535035A (ja) 2023-08-15
CA3186564A1 (en) 2022-01-27
AU2021313124A1 (en) 2023-03-09
IL299985A (en) 2023-03-01
TW202327609A (zh) 2023-07-16

Similar Documents

Publication Publication Date Title
BR112023001195A2 (pt) Composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto pró-fármaco do mesmo, composto, método de preparação para composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto de pró-fármaco, composição farmacêutica, método para tratar uma doença associada com a ativação do caminho alternativo de complemento, e, uso do composto
US20130280210A1 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
BR112017017078A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para prevenir, gerenciar, tratar ou amenizar uma doença.
CR20230310A (es) Inhibidores de prmt5
EP2309853A1 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
ECSP22019360A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
MX2010001189A (es) Derivados de naftiridina como modulares del canal de potasio.
BR112021017354A2 (pt) Método para o tratamento de doença hepática adiposa e/ou esteatoepatite
WO2021086726A8 (en) Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2
BR112023001049A2 (pt) Método para tratamento de doença de enxerto versus hospedeiro causada por transplante de célula-tronco hematopoiética
BR112022008020A2 (pt) Métodos de tratamento de doenças e distúrbios relacionados a lsd1 com inibidores de lsd1
MX2021008010A (es) Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld).
EA025948B1 (ru) КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR
BR112018072468A2 (pt) composto para uso como um inibidor de quinase, composto ou n-óxido, sal farmaceuticamente aceitável, solvato farmaceuticamente aceitável ou estereoisômero, método in vitro para inibir atividade de proteína quinase e composição farmacêutica
BR112023002553A2 (pt) Composto, composição, uso do composto e uso da composição
DOP2023000060A (es) Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención
BR112022001344A2 (pt) Combinações de antibióticos beta-lactâmicos administrados por via oral e derivados de avibactam para tratamento de infecções bacterianas
BR112022018515A2 (pt) Terapia de combinação para leucemia mieloide aguda
BR112022002107A2 (pt) Inibidor de vmat2 e método de preparação para o mesmo e aplicação do mesmo
CO2023001407A2 (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
MX2020004667A (es) Compuestos, composiciones y metodos para el tratamiento de trastornos oculares y enfermedades cutaneas.
EA200970764A1 (ru) Способ лечения расстройств, вызванных пролиферацией клеток, с применением стимуляторов секреции гормона роста
BR112023025251A2 (pt) Composto ou sal, éster, solvato, pró-fármaco, derivado marcado com isótopo ou isômero farmaceuticamente aceitável deste, composição, composição farmacêutica e método para tratamento de uma doença ou distúrbio inibindo a transdução de sinal mediada por tyk2
BR112021021600A2 (pt) Método para tratamento de tosse usando composto de diaminopirimidina